Sunflower Pharmaceuticals Group Co Ltd (002737) - Total Liabilities
Based on the latest financial reports, Sunflower Pharmaceuticals Group Co Ltd (002737) has total liabilities worth CN¥1.25 Billion CNY (≈ $182.79 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sunflower Pharmaceuticals Group Co Ltd - Total Liabilities Trend (2011–2025)
This chart illustrates how Sunflower Pharmaceuticals Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Sunflower Pharmaceuticals Group Co Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Sunflower Pharmaceuticals Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Sunflower Pharmaceuticals Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ina Invest Holding AG
SW:INA
|
Switzerland | CHF479.89 Million |
|
U Blox Holding AG
SW:UBXN
|
Switzerland | CHF104.73 Million |
|
Motus Holdings Ltd
JSE:MTH
|
South Africa | ZAC41.97 Billion |
|
Zhejiang Zhengguang Industrial Co. Ltd.
SHE:301092
|
China | CN¥228.41 Million |
|
Bangkok Chain Hospital Public Company Limited
BK:BCH-R
|
Thailand | ฿3.43 Billion |
|
Zhejiang Guyuelongshan Shaoxing Wine Co Ltd
SHG:600059
|
China | CN¥757.86 Million |
|
Tianjin Ringpu Bio Tech
SHE:300119
|
China | CN¥2.53 Billion |
|
Bio-Thera Solutions Ltd
SHG:688177
|
China | CN¥2.16 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Sunflower Pharmaceuticals Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 002737 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sunflower Pharmaceuticals Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sunflower Pharmaceuticals Group Co Ltd (2011–2025)
The table below shows the annual total liabilities of Sunflower Pharmaceuticals Group Co Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.34 Billion ≈ $195.74 Million |
+8.23% |
| 2024-12-31 | CN¥1.24 Billion ≈ $180.85 Million |
-34.16% |
| 2023-12-31 | CN¥1.88 Billion ≈ $274.70 Million |
-27.60% |
| 2022-12-31 | CN¥2.59 Billion ≈ $379.44 Million |
+52.52% |
| 2021-12-31 | CN¥1.70 Billion ≈ $248.78 Million |
-1.31% |
| 2020-12-31 | CN¥1.72 Billion ≈ $252.07 Million |
-8.36% |
| 2019-12-31 | CN¥1.88 Billion ≈ $275.05 Million |
+15.87% |
| 2018-12-31 | CN¥1.62 Billion ≈ $237.38 Million |
+23.97% |
| 2017-12-31 | CN¥1.31 Billion ≈ $191.49 Million |
-7.80% |
| 2016-12-31 | CN¥1.42 Billion ≈ $207.68 Million |
+22.97% |
| 2015-12-31 | CN¥1.15 Billion ≈ $168.89 Million |
-20.59% |
| 2014-12-31 | CN¥1.45 Billion ≈ $212.67 Million |
+18.20% |
| 2013-12-31 | CN¥1.23 Billion ≈ $179.92 Million |
+8.23% |
| 2012-12-31 | CN¥1.14 Billion ≈ $166.24 Million |
+12.08% |
| 2011-12-31 | CN¥1.01 Billion ≈ $148.33 Million |
-- |
About Sunflower Pharmaceuticals Group Co Ltd
Sunflower Pharmaceutical Group Co.,Ltd engages in the research and development, manufacturing, and marketing of Chinese patent medicines in China and internationally. The company produces chemical and biological medicines, and health care products. It also provides products covering various therapeutic areas, including pediatrics, gynecology, adult digestive system, respiratory and cold, rheumati… Read more